HUTCHMED

HCMPhase 3

HUTCHMED is a leading, innovation-driven biopharma focused on oncology and immunology, with a strategy of 'in China, for the world.' The company has successfully brought novel drugs like fruquintinib (ELUNATE®) to market in China and achieved its first global approval with Takeda. Its business model integrates discovery, development, manufacturing, and commercialization, supported by a deep pipeline of both internally discovered and in-licensed assets. HUTCHMED aims to become a global biopharmaceutical leader by advancing its pipeline through strategic global partnerships.

Market Cap

$2.4B

Employees

2000-3000

Focus

Biotech

HCM · Stock Price

USD 13.944.52 (-24.49%)

Historical price data

AI Company Overview

Technology Platform

Integrated drug discovery and development engine focused on novel small-molecule targeted therapies and immunotherapies for cancer, leveraging efficient clinical development capabilities in China.

Pipeline Snapshot

113

113 drugs in pipeline, 20 in Phase 3

Drug	Indication	Stage
Surufatinib	Neuroendocrine Tumors	Phase 3
Savolitinib + Osimertinib + Pemetrexed + Cisplatin /Carboplatin	Non-small Cell Lung Cancer	Phase 3
Savolitinib	Non-small Cell Lung Cancer Metastatic	Phase 3
Fruquintinib + Placebo	Metastatic Colorectal Cancer	Phase 3
HMPL-004 + Placebo	Ulcerative Colitis	Phase 3

Funding History

Total raised: $185M

IPO$110MUndisclosedMar 3, 2016

Series B$50MUndisclosedJun 15, 2010

Series A$25MUndisclosedJun 15, 2006

Opportunities

The global launch of fruquintinib (FRUZAQLA) with Takeda represents a major near-term revenue opportunity in the US and EU.

Further label expansions for fruquintinib and savolitinib into new cancer types and treatment lines can significantly increase their market potential.

The company's deep pipeline of novel assets provides multiple future catalysts and potential new blockbuster drugs.

Risk Factors

Key risks include intense competition in core oncology markets, potential clinical failures in late-stage pipeline programs, execution challenges in global commercial launches, and geopolitical tensions that could impact cross-border collaboration and trade.

The company's financial performance remains sensitive to royalty streams from partners.

Competitive Landscape

HUTCHMED competes globally with large pharma (Roche, AstraZeneca, Merck) and biotech companies in targeted oncology. In China, it faces competition from domestic leaders like BeiGene and Zai Lab. Its differentiation lies in its proven ability to discover and develop novel drugs, its efficient China-based R&D engine, and its strategic use of global partnerships to maximize asset value worldwide.

Publications

Patents

Pipeline

113